Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconjugated (Vi-PS) polysaccharide vaccines in preventing typhoid infection compared to a control vaccine (meningococcal ACWY), using a human challenge model of typhoid infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Therapeutic Use
- Acronyms VAST
- 15 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 03 Oct 2017 New source identified and integrated (ClinicalTrials.gov NCT02324751).
- 03 Oct 2017 Results assessing efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi, were published in the Lancet.